All 0 3 0 3 O
patients 4 12 4 12 O
who 13 16 13 16 O
have 17 21 17 21 O
received 22 30 22 30 O
anti 31 35 31 35 B-treatment
- 35 36 35 36 I-treatment
CD19 36 40 36 40 I-treatment
directed 41 49 41 49 O
CART 50 54 50 54 B-treatment
therapy 55 62 55 62 I-treatment
and 63 66 63 66 O
completed 67 76 67 76 O
or 77 79 77 79 O
discontinued 80 92 80 92 O
early 93 98 93 98 O
from 99 103 99 103 O
a 104 105 104 105 O
Novartis 106 114 106 114 B-treatment
sponsored 115 124 115 124 I-treatment
treatment 125 134 125 134 I-treatment
protocol 135 143 135 143 O
that 144 148 144 148 O
utilized 149 157 149 157 O
CD19 158 162 158 162 B-treatment
- 162 163 162 163 I-treatment
directed 163 171 163 171 I-treatment
CART 172 176 172 176 I-treatment
cells 177 182 177 182 I-treatment
or 183 185 183 185 O
from 186 190 186 190 O
any 191 194 191 194 O
CD19 195 199 195 199 B-treatment
CART 200 204 200 204 I-treatment
trial 205 210 205 210 I-treatment
sponsored 211 220 211 220 O
by 221 223 221 223 O
the 224 227 224 227 O
University 228 238 228 238 O
of 239 241 239 241 O
Pennsylvania 242 254 242 254 O
with 255 259 255 259 O
which 260 265 260 265 O
Novartis 266 274 266 274 O
has 275 278 275 278 O
a 279 280 279 280 O
contractual 281 292 281 292 O
agreement 293 302 293 302 O
to 303 305 303 305 O
co 306 308 306 308 O
- 308 309 308 309 O
develop 309 316 309 316 O
the 317 320 317 320 O
CAR 321 324 321 324 O
technology 325 335 325 335 O

